Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Shares Outstanding (Weighted Average): 2009-2024

Historic Shares Outstanding (Weighted Average) for Catalyst Pharmaceuticals (CPRX) over the last 16 years, with Dec 2024 value amounting to $119.3 million.

  • Catalyst Pharmaceuticals' Shares Outstanding (Weighted Average) rose 3.12% to $122.4 million in Q3 2025 from the same period last year, while for Mar 2024 it was $117.9 million, marking a year-over-year increase of 11.56%. This contributed to the annual value of $119.3 million for FY2024, which is 1.20% up from last year.
  • According to the latest figures from FY2024, Catalyst Pharmaceuticals' Shares Outstanding (Weighted Average) is $119.3 million, which was up 1.20% from $117.9 million recorded in FY2023.
  • In the past 5 years, Catalyst Pharmaceuticals' Shares Outstanding (Weighted Average) registered a high of $119.3 million during FY2024, and its lowest value of $103.1 million during FY2021.
  • Moreover, its 3-year median value for Shares Outstanding (Weighted Average) was $117.9 million (2023), whereas its average is $114.3 million.
  • Per our database at Business Quant, Catalyst Pharmaceuticals' Shares Outstanding (Weighted Average) declined by 0.51% in 2021 and then climbed by 11.56% in 2023.
  • Yearly analysis of 5 years shows Catalyst Pharmaceuticals' Shares Outstanding (Weighted Average) stood at $103.6 million in 2020, then decreased by 0.51% to $103.1 million in 2021, then rose by 2.46% to $105.7 million in 2022, then climbed by 11.56% to $117.9 million in 2023, then grew by 1.20% to $119.3 million in 2024.